All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Sarcoma Awareness Month 2024: Recognizing Symptoms, Scanning Patients Key to Diagnosis

July 30th 2024

During Sarcoma Awareness Month, Adam C. Berger, MD, FACS, discusses the importance of timely scans and recognizing the symptoms of sarcoma.

Mayo Clinic Study Uncovers Genetic Cancer Risks in 550 Patients

July 29th 2024

Current screening protocols fail to catch a number of people carrying genetic mutations associated with hereditary breast and ovarian cancer syndrome.

FDA Extends PDUFA Date for Revumenib in KMT2A-Rearranged Acute Leukemia

July 29th 2024

The FDA has extended the PDUFA date for the NDA seeking the approval of revumenib for patients with relapsed/refractory KMT2A-rearranged acute leukemia.

China’s NMPA Accepts sBLA for Ivonescimab in First-Line PD-L1+ NSCLC

July 29th 2024

China’s NMPA has accepted an sBLA for ivonescimab in first-line, PD-L1–positive non–small cell lung cancer.

Shield Blood Test Receives FDA Approval for CRC Screening in Adults

July 29th 2024

The Shield blood test has been approved by the FDA for CRC screening in adults aged 45 years and older who are at average risk for the disease.

CHMP Recommends Toripalimab Plus Chemo for Metastatic Nasopharyngeal Carcinoma and Advanced ESCC

July 29th 2024

The EMA’s CHMP has recommended toripalimab plus chemotherapy for metastatic nasopharyngeal carcinoma and advanced esophageal squamous cell carcinoma.

Fixed-Duration Acalabrutinib/Venetoclax Yields PFS Benefit vs SOC in Frontline CLL

July 29th 2024

Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab elicited favorable PFS outcomes in previously untreated chronic lymphocytic leukemia.

Experts Delve into Case-Based Discussions of Locally Advanced Lung Cancer Management

July 29th 2024

A panel of oncologists engage in a case-based discussion of patients with locally advanced disease at the 25th Annual International Lung Cancer Congress.

Tolaney Details IHC Testing Considerations for HER2-Low TNBC and Data on ADCs

July 29th 2024

Sara M. Tolaney, MD, MPH, shares biopsy considerations when determining HER2-low status for patients with TNBC and details data within the TNBC landscape.

ctDNA Carves a Precise Path for Early-Stage NSCLC Management

July 29th 2024

David R. Gandara, MD, discusses research reflecting the capabilities of ctDNA assays to detect MRD and prognosticate adjuvant NSCLC treatment outcomes.

Tarantino Talks Limitations in HER2-Low Breast Cancer Management, Key Advancements in HER2+/TNBC

July 28th 2024

Paolo Tarantino, MD, discusses current treatment landscapes and looks to the future in HER2-low breast cancer, HER2-positive breast cancer, and TNBC.

Pembrolizumab Plus Chemo Elicits Responses in Head and Neck Squamous Cell Carcinoma

July 27th 2024

Frontline pembrolizumab, carboplatin, and paclitaxel demonstrated antitumor activity in recurrent or metastatic head and neck squamous cell carcinoma.

Mendoza, Weiss Receive $2.6 Million Grant to Study Biomechanics of Lung Tumors

July 26th 2024

Michelle Mendoza, PhD, and Jeffrey Weiss, PhD, received a $2.6 million grant from the NIH to research how tension in lung tissue affects the growth and distribution of tumors.

Zolbetuximab Plus Chemo Approaches EU Approval for Advanced Gastric/GEJ Cancer

July 26th 2024

The EMA's CHMP has recommended zolbetuximab plus chemotherapy in select locally advanced unresectable or metastatic HER2-negative gastric or GEJ cancer.

CHMP Recommends Amivantamab Plus Chemo for Pretreated EGFR+ Advanced NSCLC

July 26th 2024

The EMA’s CHMP has recommended the approval of amivantamab plus chemotherapy for pretreated, EGFR-mutated advanced non–small cell lung cancer.

First-Line Sugemalimab Plus Chemo Wins European Approval for Metastatic NSCLC

July 26th 2024

First-line sugemalimab plus chemotherapy has been approved in Europe for metastatic non–small cell lung cancer.

Pembrolizumab Plus Enfortumab Vedotin Earns CHMP Recommendation in Frontline Metastatic Urothelial Carcinoma

July 26th 2024

The CHMP has recommended pembrolizumab plus enfortumab vedotin-ejfv in frontline unresectable or metastatic urothelial carcinoma.

Experts Weigh in on Topic of Frontline Osimertinib Alone or With Chemo in EGFR-Mutant NSCLC

July 26th 2024

Jonathan W. Riess, MD, MS, and James Chih-Hsin Yang MD, PhD, debate the benefits of upfront osimertinib with/without chemotherapy in EGFR-mutant NSCLC.

From Targetless to Targetable, Breakthroughs Push Forward in TNBC Treatment Landscape

July 26th 2024

Sara M. Tolaney, MD, MPH, discusses the transformation of treatments for patients with triple-negative breast cancer.

Changes in HER2+ Breast Cancer May Include Tailored Therapy With pCR, Use of T-DXd

July 26th 2024

Adrienne G. Waks, MD, discusses the potential for pCR-guided treatment and highlights therapies for patients with residual disease beyond T-DM1.